Please login to the form below

Not currently logged in
Email:
Password:

Hypertrophic cardiomyopathy

This page shows the latest Hypertrophic cardiomyopathy news and features for those working in and with pharma, biotech and healthcare.

BMS builds case for cardiovascular drug mavacamten with new analysis

BMS builds case for cardiovascular drug mavacamten with new analysis

Bristol Myers Squibb has reported some new analysis for its investigational cardiovascular drug mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). ... Hypertrophic cardiomyopathy (HCM) is a chronic and progressive disease which

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    For a registry study, Novartis asked patients to complete the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which tracks physical limitations, symptom frequency, social limitation and quality of life. ... MyoKardia is gathering PROs in its

  • Pharma deals during September 2014 Pharma deals during September 2014

    develop two HCM (hypertrophic cardiomyopathy) programmes where it retains US commercialisation rights and Sanofi has ex-US rights; and a third DCM (dilated cardiomyopathy) programme will be developed by Sanofi with

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    MyoKardia's genetically targeted approach and cutting-edge platform has the potential to fundamentally change the lives of patients with hypertrophic cardiomyopathy and dilated cardiomyopathy,” he said.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The power of communication: Engaging diverse groups in healthcare
Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...
Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....